Previous 10 | Next 10 |
2024-05-12 17:35:55 ET Major earnings expected after the bell on Monday include: Petróleo Brasileiro S.A. - Petrobras ( PBR ) Lithium Americas (Argentina) Corp. ( LAC ) StoneCo Ltd. ( STNE ) Inovio Pharmaceuticals ( INO ) Alcon ( ALC ) ...
2024-05-12 17:35:00 ET More on Harrow Health Harrow: Merits A Buy On Sales Potential Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom Harrow, Inc. (HROW) Q4 2023 Earnings Call Transcript Harrow Health Q4 2023 Earnings Preview Seekin...
2024-05-02 12:20:24 ET Summary Harrow, Inc. shares have dropped 45% since spring 2023, but the launch of Iheezo and Vevye suggest a potential rebound. Iheezo, an ocular anesthetic, has a substantial market opportunity and is expected to drive significant revenue for Harrow. Ve...
2024-05-02 04:42:01 ET Summary Harrow's long-term bull thesis is stronger than ever, but there may be a credible short-term bear thesis. The short-term bear thesis is the result of the Change Healthcare cyberattack, which has crippled reimbursement and caused huge financial headac...
2024-05-01 22:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on May 14, 2024 Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after ...
2024-04-12 17:05:37 ET Gainers: Applied Optoelectronics ( AAOI ) +5% . Eliem Therapeutics ( ELYM ) +4% . Infinera Corporation ( INFN ) +4% . Harrow ( HROW ) +4% . Health Catalyst ( HCAT ) +4% . Losers: Eagle Pharmaceutica...
MELT-300 Pivotal Phase 3 Program Topline Readout Expected in Q4 2024 Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of its Series B Preferred Stock fina...
2024-03-20 10:14:11 ET Harrow, Inc. (HROW) Q4 2023 Earnings Conference Call March 20, 2024 08:00 A.M. ET Company Participants Jamie Webb - Director-Communications & IR Mark L. Baum - Chairman and CEO Andrew R. Boll - CFO Conference Call Participants ...
2024-03-20 08:11:18 ET More on pre-market losers & stocks. Prudential: Consider Both Upcoming Results And 2024 Risk Factors Euronav NV: Not Backing Down On The Decarbonization Agenda Euronav NV 2023 Q4 - Results - Earnings Call Presentation Solidion Techn...
News, Short Squeeze, Breakout and More Instantly...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...